LIMN liminatuspharma.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Liminatus Pharma focuses on creating innovative methods to combat gastrointestinal oncology. This price chart demonstrates an EV/EBITDA ratio of 0.00. A team of top-tier biochemists is developing a CAR-T platform to capture market share in solid tumor therapy. The strategy relies on the expansion of clinical trials, while investment potential depends on the success of these trials and the inflow of capital.

When selecting defensive assets, the priority becomes identifying undervalued business value relative to operating profit. By outsourcing production and testing to external contractors, Liminatus Pharma (LIMN) minimizes capital expenditures, making changes in the company's EV/EBITDA level a key indicator of the ratio between total enterprise value and its ability to generate cash flow before interest and taxes.